Episode 400: 408. CME Obesity and MASH

Episode 400: 408. CME Obesity and MASH

  • GLP1 drugs work but they likely need lifestyle modifications


  • No convincing evidence GLP1 cause thyroid cancer in humans BUT contraindication if family history exist


  • Stopping therapy usually results in weight gain


  • Insurance coverage for weight loss is limited and variable


  • Semaglutide for type 2 diabetes max dose is 2.0 mg weekly Semaglutide for weight loss has a goal dose of 2.4 mg weekly
  • Diagnose steatotic liver disease with imaging and 1 metabolic risk factor (or biopsy)


  • After diagnosis check FIB-4:
    • Low risk, continue to monitor with FIB-4 every 2-3yrs
    • Intermediate risk, order VCTE and consider referral if >F1
    • High risk order a VCTE and referral (20% end with SLD)


  • 2 FDA approved medications for liver fibrosis are not cheap, expect insurance push back


Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(401)

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
psykodrama
fryktlos
hvordan-har-du-det-mann
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-skravla-gar
foreldreradet
rss-ekteskapet
klimaks
morten-ramm-lar-kakla-ga-til-du-sovner
treningsprat
rss-kunsten-a-leve
g-punktet
rss-lopedrommen
rss-loping-for-nybegynnere
rss-kull
kjed-deg-i-sovn-verdens-kjedeligste-podcast